Japan Hosts US$8.65 Billion in API-Related Pharma Projects

---

Researched by Industrial Info Resources (Sugar Land, Texas)--KM Biologics Company Limited (Kumamoto, Japan) is expanding its bulk active pharmaceutical ingredient (API) single-use systems (SUS) plant in Kumamoto, Japan. The facility will increase its production of the "four-in-one" vaccine, the Japanese encephalitis vaccine and, when necessary, vaccines for pandemics.

Construction is expected to begin in the third quarter of 2025 and wrap up in 2027. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project and Plant databases can learn more from a detailed project report and plant profile.

Industrial Info is tracking about 68 capital-spending projects in Japan's Pharmaceutical & Biotech Industry geared toward the production of APIs, totaling more than US$8.65 billion in investment value. Subscribers can click here for a list of detailed project reports and click here for a list of related plant profiles.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) platform helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 trillion (USD).